PT  - JOURNAL ARTICLE
AU  - Hippisley-Cox, Julia
AU  - Mei, Xue W
AU  - Tan, Pui San
AU  - Fitzgerald, Rebecca
AU  - Coupland, Carol
AU  - Panday-Ghimire, Bhagabati
AU  - Offman, Judith
AU  - Sasieni, Peter
TI  - Chronic acid-suppressant use and risk of Oesophageal cancer: protocol for a longitudinal study using a large population based cohort
AID  - 10.1101/2021.02.15.21251618
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.15.21251618
4099  - http://medrxiv.org/content/early/2021/02/18/2021.02.15.21251618.short
4100  - http://medrxiv.org/content/early/2021/02/18/2021.02.15.21251618.full
AB  - Introduction Oesophageal cancer is the sixth most common cause for cancer related deaths with over 450,000 new cases and 400,000 resulting deaths per year globally. Most cases in the UK are adenocarcinoma with some of the poorest outcomes from this cancer type in Europe -- mainly due to late diagnosis. The main risk factor for oesophageal adenocarcinoma is chronic reflux disease and due to the high prevalence and non-specific nature of these symptoms most patients are often managed with acid-reflux medications (e.g. Proton Pump Inhibitors (PPIs)) without referral for endoscopy. For those patients that are referred the endoscopy is normal in over 70% of cases, and there is not enough capacity within the NHS for endoscopy especially considering colon cancer screening.The primary aim of this project is to improve early identification of individuals at risk of oesophageal cancer and reduce over-use of prescription antacids.Methods and analysis We will conduct a longitudinal cohort study consisted of adults 40 years and over who are free of oesophageal cancer at study entry, using the QResearch database for data gathered between 2000 and 2020. The main exposure is the use of prescription antacids which includes PPI, H2RA, and other aluminium and magnesium containing antacids. The exposure will be categorised based on active ingredients, dose, and duration of use and will be modelled as a time-varying covariate.Ethics and dissemination Ethical approval for this project was obtained from the QResearch Scientific Committee [Ref: OX39, project title “DELTA - integrated Diagnostic solution for Early detection of Oesophageal cAncer”]. This project has been supported by patient and public involvement panels. We intend to submit the findings for peer-reviewed publication in an academic journal and disseminate them to the public.Strength and limitations of this studyThis is an open cohort study comprising a nationally representative sample of English population.The cohort consists of GP clinic data linked to hospital records, the English national cancer registry and English national death registry.This study has access to detailed information on acid-suppressant prescriptions, allowing analysis with consideration of the specific compound, dose, and duration of exposure.This study is limited by high rates of missing data for cancer grade and stage, although completeness has improved in recent years, this will be accounted for using appropriate multiple imputation techniques.Competing Interest StatementThe authors have declared no competing interest.Funding StatementQResearch receives infrastructure support from NIHR Oxford Biomedical Research Centre; the Medical Sciences Division of the University of Oxford; John Fell Oxford University Press Research Fund; the Oxford Wellcome Institutional Strategic Support Fund (204826/Z/16/Z); Cancer Research UK (CR-UK) grant number C5255/A18085, through the Cancer Research UK Oxford Centre. It also receives contributions in kind from EMIS Health (commercial supplier of NHS health computer systems).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol has been reviewed in accordance with the requirements for the East Midlands Derby research ethic committee (ref 18/EM/0400) and approved on 02/11/2021 (reference OX39)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available and can be accessed by members of the project team undertaking statistical analysis